MX2021014448A - Modulacion de celulas mieloides estimulantes y no estimulantes. - Google Patents

Modulacion de celulas mieloides estimulantes y no estimulantes.

Info

Publication number
MX2021014448A
MX2021014448A MX2021014448A MX2021014448A MX2021014448A MX 2021014448 A MX2021014448 A MX 2021014448A MX 2021014448 A MX2021014448 A MX 2021014448A MX 2021014448 A MX2021014448 A MX 2021014448A MX 2021014448 A MX2021014448 A MX 2021014448A
Authority
MX
Mexico
Prior art keywords
stimulatory
myeloid cells
modulation
antigen binding
stimulatory myeloid
Prior art date
Application number
MX2021014448A
Other languages
English (en)
Inventor
Matthew Krummel
Miranda Broz
Denise Wolf
Joshua Pollack
Mikhail Binnewies
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2021014448A publication Critical patent/MX2021014448A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243Colony Stimulating Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429Molecules with a "CD" designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0625Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0626Melanocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0645Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0693Tumour cells; Cancer cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

En la presente se proporcionan métodos y composiciones para mejorar una respuesta inmunitaria y/o para el tratamiento de una afección relacionada con la respuesta inmunitaria en un individuo, por ejemplo, cáncer, que comprende la destrucción, inactivación o reducción de células mieloides no estimulantes con una proteína de unión al antígeno tal como un anticuerpo o fragmento de unión al antígeno de este.
MX2021014448A 2014-09-28 2017-03-27 Modulacion de celulas mieloides estimulantes y no estimulantes. MX2021014448A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056569P 2014-09-28 2014-09-28
US201562129883P 2015-03-08 2015-03-08

Publications (1)

Publication Number Publication Date
MX2021014448A true MX2021014448A (es) 2022-01-06

Family

ID=55582160

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004007A MX2017004007A (es) 2014-09-28 2015-09-28 Modulacion de celulas mieloides estimulantes y no estimulantes.
MX2021014448A MX2021014448A (es) 2014-09-28 2017-03-27 Modulacion de celulas mieloides estimulantes y no estimulantes.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017004007A MX2017004007A (es) 2014-09-28 2015-09-28 Modulacion de celulas mieloides estimulantes y no estimulantes.

Country Status (12)

Country Link
US (3) US10428143B2 (es)
EP (1) EP3197495A4 (es)
JP (3) JP6811711B2 (es)
KR (3) KR102506663B1 (es)
CN (1) CN106999585A (es)
AU (3) AU2015319809B2 (es)
CA (1) CA2961950A1 (es)
EA (1) EA034921B1 (es)
IL (3) IL294043B1 (es)
MX (2) MX2017004007A (es)
WO (1) WO2016049641A1 (es)
ZA (1) ZA201701658B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3081576T1 (sl) 2013-12-12 2019-12-31 Shanghai Hengrui Pharmaceutical Co., Ltd., Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR102506663B1 (ko) * 2014-09-28 2023-03-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
US11249081B2 (en) 2016-08-31 2022-02-15 Agency For Science, Technology And Research Methods for the identification, targeting and isolation of human dendritic cell (DC) precursors “pre-DC” and their uses thereof
JP7089507B2 (ja) * 2016-09-26 2022-06-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Pd-1軸阻害剤への応答を予測すること
WO2018147291A1 (en) 2017-02-07 2018-08-16 Saitama Medical University Immunological biomarker for predicting clinical effect of cancer immunotherapy
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
AU2018311055A1 (en) 2017-08-03 2019-11-14 Alector Llc Anti-TREM2 antibodies and methods of use thereof
WO2019032624A1 (en) * 2017-08-08 2019-02-14 Pionyr Immunotherapeutics, Inc. COMPOSITIONS AND METHODS FOR DEACTIVATING TREM1-EXPRESSING MESHLOID CELLS
CA3079999A1 (en) * 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
MX2020005128A (es) 2017-11-17 2020-07-27 Merck Sharp & Dohme Anticuerpos especificos para el transcrito similar a la inmunoglobulina tipo 3 (ilt3) y sus usos.
CN111712258B (zh) 2017-12-12 2024-03-15 开拓免疫医疗公司 抗trem2抗体和相关方法
CN108085393B (zh) * 2018-01-31 2020-06-02 青岛泱深生物医药有限公司 肾透明细胞癌相关生物标志物及其应用
KR20200142498A (ko) * 2018-02-02 2020-12-22 온코이뮨, 아이앤씨. 암 치료를 위한 더 안전하고 더 효과적인 항-ctla-4 항체를 선택하고 설계하는 방법
WO2020002766A1 (en) * 2018-06-21 2020-01-02 Faron Pharmaceuticals Oy Treatment of cancer with clever-1 inhibition in combination with pd-1/pd-l1 inhibitor
EP3810756A4 (en) * 2018-06-25 2022-03-23 Peter MacCallum Cancer Institute MODIFIED T LYMPHOCYTES AND THEIR USES
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CN109609463B (zh) * 2019-01-10 2022-07-01 中国医学科学院肿瘤医院 一种宫颈癌肿瘤原代细胞分离及培养方法
US10836828B2 (en) 2019-02-06 2020-11-17 Pionyr Immunotherapeutics, Inc. Anti-TREM1 antibodies and related methods
JPWO2020171141A1 (es) * 2019-02-20 2020-08-27
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2020247290A1 (en) * 2019-06-04 2020-12-10 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
KR20220056186A (ko) * 2019-08-13 2022-05-04 고쿠리츠다이가쿠호진 도호쿠다이가쿠 면역 체크포인트 저해제, 면역 체크포인트 관련 질환의 치료제, 면역 억제제, 항피브로넥틴 항체 또는 그 유도체, 피브로넥틴 아날로그, 피브로넥틴 또는 그 부분 단백질을 검출하기 위한 키트, 및 피브로넥틴 또는 그 부분 단백질을 검출하는 방법
JP2022546592A (ja) 2019-09-03 2022-11-04 マイエロイド・セラピューティクス,インコーポレーテッド ゲノム組込みのための方法および組成物
CN110836974B (zh) * 2019-11-07 2022-09-09 西安交通大学医学院第一附属医院 Flt3lg蛋白在制备肺腺癌术后预后评估试剂或者试剂盒中的应用
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
JP2023507110A (ja) 2019-12-19 2023-02-21 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド Ilt3結合剤及びその使用方法
BR112022013756A2 (pt) 2020-01-13 2022-10-11 Denali Therapeutics Inc Anticorpos anti-trem2 e métodos de uso dos mesmos
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
EP4136114A1 (en) * 2020-04-14 2023-02-22 Les Laboratoires Servier Anti-flt3 antibodies and compositions
WO2022057910A1 (en) * 2020-09-17 2022-03-24 I-Mab Biopharma Co., Ltd Combination therapies targeting c5ar and pd-1/pd-l1 pathways
AU2021376354A1 (en) 2020-11-04 2023-06-22 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重car-t組成物及び方法
CA3207815A1 (en) * 2021-03-09 2022-09-15 Desmond Mascarenhas Modulation of mammalian cell lineage by synthetic immodulins
IL311337A (en) * 2021-09-08 2024-05-01 Joint Stock Company «Biocad» A bispecific antibody that includes a heterogeneous dimer based on MHC proteins
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
AU2022376954A1 (en) 2021-10-29 2024-05-02 Gilead Sciences, Inc. Cd73 compounds
WO2023094436A1 (en) * 2021-11-26 2023-06-01 Technische Universität Dresden Placental macrophages for cell therapy
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
EP4245756A1 (en) 2022-03-17 2023-09-20 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Kras g12d調節化合物
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US7442777B2 (en) 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) * 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20070213660A1 (en) 2004-10-29 2007-09-13 Mark Richards Fibrin sealant delivery device including pressure monitoring, and method and kits thereof
EP1882392A4 (en) 2005-05-10 2009-07-01 Monsanto Technology Llc GENES AND THEIR USES FOR PLANT IMPROVEMENTS
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US20090202544A1 (en) * 2006-02-02 2009-08-13 The Trustees Of Columbia University In The City Of New York Methods of Treating Diseases by Targeting Silt3
US7777008B2 (en) 2006-06-19 2010-08-17 Tolerx, Inc. ILT3 binding molecules and uses therefor
CA2785964C (en) 2009-12-29 2021-03-30 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
CA2793657A1 (en) * 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
US20110262348A1 (en) * 2010-03-29 2011-10-27 Vrije Universiteit Brussel Selective targeting of intratumoral cells
US20140045915A1 (en) * 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
US8427899B2 (en) * 2010-10-29 2013-04-23 Taiwan Semiconductor Manufacturing Company, Ltd. Self-adaptive sensing design
CN103608028A (zh) * 2011-04-28 2014-02-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
WO2013033734A1 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of Cancer Expressing ILT3 or ILT3 Ligand
AU2013265665B2 (en) * 2012-05-24 2017-10-26 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US20150191543A1 (en) 2012-08-06 2015-07-09 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
SG11201503469WA (en) 2012-11-07 2015-06-29 Pfizer Anti-notch3 antibodies and antibody-drug conjugates
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
MX2015007846A (es) * 2012-12-19 2016-04-28 Amplimmune Inc Anticuerpos anti-b7-h4 humana y sus usos.
WO2014135245A1 (en) * 2013-03-05 2014-09-12 Merck Patent Gmbh 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20160220692A1 (en) * 2013-09-09 2016-08-04 The Johns Hopkins University Targeting the m2-tumor associated macrophage for cancer therapy
US20170240631A1 (en) * 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR102506663B1 (ko) 2014-09-28 2023-03-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
WO2016064895A1 (en) 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Targeting apolipoprotein e (apoe) in neurologic disease
US10221248B2 (en) * 2014-12-22 2019-03-05 The Rockefeller University Anti-MERTK agonistic antibodies and uses thereof
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
US20190330335A1 (en) 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
US10941200B2 (en) 2016-07-22 2021-03-09 Deutsches Zentrum Für Neurodegenerative Erkrankungen Ev TREM2 cleavage modulators and uses thereof
US10167796B2 (en) 2017-05-17 2019-01-01 GM Global Technology Operations LLC Gasoline particulate filter regeneration strategy
WO2019021233A1 (en) 2017-07-27 2019-01-31 Novartis Ag TREM2 VARIANTS RESISTANT TO SHEDDASE
AU2018311055A1 (en) 2017-08-03 2019-11-14 Alector Llc Anti-TREM2 antibodies and methods of use thereof
EP3681909A1 (en) 2017-09-14 2020-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
CN111712258B (zh) 2017-12-12 2024-03-15 开拓免疫医疗公司 抗trem2抗体和相关方法
JP2022514734A (ja) 2018-12-11 2022-02-15 パイオニア イミュノセラピューティクス インコーポレイテッド 抗trem2抗体の使用方法

Also Published As

Publication number Publication date
IL283834A (en) 2021-07-29
IL294043A (en) 2022-08-01
AU2015319809A1 (en) 2017-05-18
JP2023017834A (ja) 2023-02-07
JP2021063086A (ja) 2021-04-22
US11325973B2 (en) 2022-05-10
IL294043B1 (en) 2024-06-01
IL251020B (en) 2021-06-30
EP3197495A1 (en) 2017-08-02
US10428143B2 (en) 2019-10-01
KR20230035458A (ko) 2023-03-13
AU2020200678B2 (en) 2022-01-27
JP7168641B2 (ja) 2022-11-09
KR20240056629A (ko) 2024-04-30
WO2016049641A1 (en) 2016-03-31
US20220411496A1 (en) 2022-12-29
EA201790755A1 (ru) 2017-10-31
US20200017584A1 (en) 2020-01-16
KR102506663B1 (ko) 2023-03-08
EP3197495A4 (en) 2018-08-29
IL283834B (en) 2022-07-01
AU2020200678A1 (en) 2020-02-20
ZA201701658B (en) 2018-04-25
US20170291946A1 (en) 2017-10-12
KR102659538B1 (ko) 2024-04-22
EA034921B1 (ru) 2020-04-07
CN106999585A (zh) 2017-08-01
CA2961950A1 (en) 2016-03-31
AU2015319809B2 (en) 2020-02-06
MX2017004007A (es) 2018-05-07
KR20170061152A (ko) 2017-06-02
JP2017538664A (ja) 2017-12-28
AU2022202730A1 (en) 2022-05-19
JP6811711B2 (ja) 2021-01-13
IL251020A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
MX2021014448A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
NZ738008A (en) Tigit-binding agents and uses thereof
PH12016501644B1 (en) Binding proteins and methods of use thereof
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
EP3964527A3 (en) Combination therapy for cancer
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201807920B (en) Anti¿gitr antibodies and uses thereof
WO2015109124A3 (en) Immunomodulatory agents
BR112017008710A2 (pt) composições e métodos para estimular a eficácia de imunoterapia celular adotiva
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
PH12016501366A1 (en) Novel anti-baff antibodies
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
MX2017000775A (es) Vacunas de meningococos.
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
MX2022015197A (es) Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
MX2017011991A (es) Terapia virica con una combinacion de anticuerpos.
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.
NZ728041A (en) Substances and methods for the use in prevention and/or treatment in huntington’s disease
IN2014CN00547A (es)
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2021009500A (es) Anticuerpos anti-trem1 y metodos relacionados.
EA202090201A3 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток